DNAVision Orders Europe’s Second and Benelux First HISeq2000™ for Commercial Use
News Feb 09, 2010
DNAVision announces the purchase of Illumina’s new HiSeq 2000™ sequencing platform, which has officially been launched three weeks ago.
Illumina’s latest sequencing system will be installed in Gosselies’facility and implemented in the high quality certifications environment. This latest acquisition will further strengthen DNAVision’s current portfolio of next generation sequencing services on GA IIx and Roche 454.
Initially, DNAVision will employ the HiSeq 2000™ for human genome sequencing projects for its pharmaceutical and medical research customers.
“As DNAVision already has Illumina CSPro certification in place and is the only genomics company in the world to be ISO17025 accredited, CLIA certified, CAP accredited, GLP certified and GMP certified, we are pretty confident that we will produce human genome data with any quality certification requested. We want to be the first company to provide human genome sequencing data deemed suitable for medical purposes and move with this breakthrough technology to personalized medicine” says Jean-Pol Detiffe, CEO of DNAVision. Illumina’s HiSeq 2000™ with the estimated output of 200 GB per run allows us to virtually sequence 2 human genomes at 30x coverage in a week.
Previous work by the International Multiple Sclerosis Genetics Consortium (IMSGC) has identified 233 genetic risk variants. However, these only account for about 20% of overall disease risk, with the remaining genetic culprits proving elusive. A new study has tracked down four of these hard-to-find genes.READ MORE